Skip to main content

  • FDA issues letter on paclitaxel devices after reports of increased risk in peripheral treatment

    FDA issues letter on paclitaxel devices after reports of increased risk in peripheral treatment

  • FDA issues letter on paclitaxel devices after reports of increased risk in peripheral treatment

    ‘Benefits continue to outweigh risks,’ agency says

    The U.S. Food and Drug Administration (FDA) said Thursday, Jan. 17, 2019, that it is evaluating information concerning the potential for increased long-term mortality after the use of paclitaxel-coated devices to treat peripheral arterial disease in the femoral or popliteal artery.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details